Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics’ partner Atturos has successfully transferred the PromarkerD technologies to laboratories in Ireland
- The technology transfer coincides with the publication of the PromarkerD study results in the Journal of Diabetes and its Complications
- PromarkerD is a diagnostic test for diabetic kidney disease
- Proteomics is now in discussions with international companies to expand the global reach of PromarkerD
Med-tech company Proteomics’ partner Atturos has successfully transferred the PromarkerD technology to laboratories in Ireland.
PromarkerD is Proteomics’ world-leading diagnostic test for diabetic kidney disease and will now be available as a mass spectrometry laboratory test to licence partners in the European market.
“We are excited to be able to offer the test in Europe for the first time, and are working hard to give patients around the world the opportunity to know their diabetic kidney disease status,” Proteomics Managing Director Dr Richard Lipscombe said.
The completion of the technology transfer coincides with the publication of the PromarkerD study results in the Journal of Diabetes and its Complications.
These results confirm that PromarkerD could correctly predict 86 per cent of diabetes patients who went on the develop chronic kidney disease within four years.
Working with Proteomics scientists, Atturos have undertaken a strict validation process of the PromarkerD method.
The results of this successful cross-over study will be presented in the Precision Medicine and Clinical Proteomics section of the 18th Human Proteome Organisation World Congress.
This will be held in Adelaide from September 15 to 18, 2019.
PromarkerD is a ground-breaking technology that takes advantage of the omnipresent proteins in the human body.
The Promarker platform uses mass spectrometry-based technology to identify the proteins that can be used as a biological marker of diseases and other conditions.
“With dialysis treatment costing approximately €80,000 per year, PromarkerD has the potential to save patients and healthcare systems billions of dollars,” Dr Richard commented.
Currently in Europe diabetes affects 59 million people with that number expected to rise to 67 million people by 2045.
An estimated one in three adults with diabetes already have chronic kidney disease. With early intervention it is possible to delay or prevent clinical symptoms of the disease.
Proteomics is now in international discussions with tier-1 diagnostics and pharmaceutical companies specifically in Europe, India, Japan and the U.S.A. to expand the global reach of PromarkerD.
